{
  "completed": true,
  "status": "documented_historical_discovery_and_reconciliation",
  "provider": "Consensus",
  "provider_mode": "Historical browser/connector use as recorded in the source artifacts",
  "local_audit_date": "2026-10-09",
  "primary_comparison_count": null,
  "reported_usage": [
    {
      "path": "D:\\HypothesisCritic\\deliverables\\hsef_v53_popularity_ranks_41_45_2026-10-08\\antimicrobial-amyloid\\consensus\\usage.json",
      "metrics": {
        "deep_queries": 0,
        "api_calls": 0,
        "browser_pro_queries": 2,
        "targeted_studies_requested": 8,
        "original_passage_comparisons": 3
      }
    }
  ],
  "grade_changed": false,
  "score_before": {
    "hsef_level": "Β",
    "hsef_descriptor": "Associational",
    "confidence": "Moderate",
    "confidence_rationale": "61 primary reports with 6 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.",
    "rests_on_non_peer_reviewed_work": false,
    "rationale": "The preregistered weakest-link rule yields Β from SC6. Direct human support for net protective pathogen-centered plaques is localization and ex vivo activity, without functional necessity, temporal demonstration or infection-stratified benefit. SC1–5 have mechanistic or simplified-model support (Γ); neither APP receptor immunity nor clinical antibody efficacy proves the nominal protective mechanism. This grade does not deny in vitro activity or refute all pathogen contributions."
  },
  "score_after": {
    "hsef_level": "Β",
    "hsef_descriptor": "Associational",
    "confidence": "Moderate",
    "confidence_rationale": "61 primary reports with 6 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.",
    "rests_on_non_peer_reviewed_work": false,
    "rationale": "The preregistered weakest-link rule yields Β from SC6. Direct human support for net protective pathogen-centered plaques is localization and ex vivo activity, without functional necessity, temporal demonstration or infection-stratified benefit. SC1–5 have mechanistic or simplified-model support (Γ); neither APP receptor immunity nor clinical antibody efficacy proves the nominal protective mechanism. This grade does not deny in vitro activity or refute all pathogen contributions."
  },
  "independent_blinded_audit": false,
  "raw_receipts": [
    {
      "path": "deliverables\\hsef_v53_neurodegeneration_2026-10-03\\antimicrobial-amyloid\\consensus\\consensus-evidence-cards.json",
      "sha256": "b9161e4fe09f878240f5cced21cc147f52f3e2aca25c4b51b80dd122a26dcb79"
    },
    {
      "path": "deliverables\\hsef_v53_neurodegeneration_2026-10-03\\antimicrobial-amyloid\\consensus\\consensus-evidence-cards.md",
      "sha256": "041200191e1c711476851abd8e7674a624873be375270715244cd54f481651b9"
    },
    {
      "path": "deliverables\\hsef_v53_neurodegeneration_2026-10-03\\antimicrobial-amyloid\\discovery\\consensus-discovery.json",
      "sha256": "eb129a8983428df6194e4c70e5ec38a73681f09ddcc913e3f9eb84063b7bc5d5"
    },
    {
      "path": "deliverables\\hsef_v53_popularity_ranks_41_45_2026-10-08\\antimicrobial-amyloid\\consensus\\broad-ax.txt",
      "sha256": "f0adadb31bb1bb75b2c5b94d437a8d62a9bb21a0e006361886b4d1c4bfad0ec9"
    },
    {
      "path": "deliverables\\hsef_v53_popularity_ranks_41_45_2026-10-08\\antimicrobial-amyloid\\consensus\\reconciliation.md",
      "sha256": "0fb45f06624435cb0e4da26a5f77621c48b7371fe8b370151439bb9ba7764ae1"
    }
  ],
  "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record."
}